KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Other financing activities (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Other financing activities for 16 consecutive years, with -$889000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other financing activities fell 845.74% year-over-year to -$889000.0, compared with a TTM value of -$889000.0 through Dec 2025, up 72.02%, and an annual FY2025 reading of -$889000.0, up 72.02% over the prior year.
  • Other financing activities was -$889000.0 for Q4 2025 at Biomarin Pharmaceutical, down from -$94000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $703000.0 in Q2 2021 and bottomed at -$9.5 million in Q4 2023.
  • Average Other financing activities over 5 years is -$1.5 million, with a median of -$94000.0 recorded in 2024.
  • The sharpest move saw Other financing activities plummeted 86933.33% in 2022, then skyrocketed 99.01% in 2024.
  • Year by year, Other financing activities stood at $3000.0 in 2021, then tumbled by 86933.33% to -$2.6 million in 2022, then plummeted by 265.45% to -$9.5 million in 2023, then surged by 99.01% to -$94000.0 in 2024, then crashed by 845.74% to -$889000.0 in 2025.
  • Business Quant data shows Other financing activities for BMRN at -$889000.0 in Q4 2025, -$94000.0 in Q4 2024, and -$3.0 million in Q3 2024.